Guines Llc Acquires 43,378 Shares of biote Corp. (NASDAQ:BTMD) Stock

biote Corp. (NASDAQ:BTMDGet Free Report) major shareholder Guines Llc bought 43,378 shares of biote stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average price of $3.15 per share, with a total value of $136,640.70. Following the purchase, the insider now owns 4,107,987 shares of the company’s stock, valued at $12,940,159.05. This trade represents a 1.07 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Guines Llc also recently made the following trade(s):

  • On Thursday, April 3rd, Guines Llc purchased 7,321 shares of biote stock. The stock was purchased at an average cost of $3.24 per share, with a total value of $23,720.04.
  • On Monday, March 31st, Guines Llc acquired 106,000 shares of biote stock. The shares were purchased at an average cost of $3.32 per share, for a total transaction of $351,920.00.
  • On Monday, March 17th, Guines Llc bought 100 shares of biote stock. The stock was purchased at an average price of $3.74 per share, with a total value of $374.00.
  • On Thursday, March 13th, Guines Llc purchased 750,000 shares of biote stock. The stock was acquired at an average cost of $3.22 per share, for a total transaction of $2,415,000.00.

biote Stock Performance

BTMD stock opened at $3.25 on Wednesday. biote Corp. has a 1-year low of $3.04 and a 1-year high of $8.44. The business’s 50 day moving average is $4.20 and its 200-day moving average is $5.25. The firm has a market cap of $177.81 million, a P/E ratio of 12.50 and a beta of 1.17.

Institutional Trading of biote

Large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its stake in shares of biote by 0.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company’s stock valued at $4,211,000 after purchasing an additional 3,065 shares in the last quarter. State Street Corp lifted its holdings in biote by 13.7% during the 3rd quarter. State Street Corp now owns 475,491 shares of the company’s stock valued at $2,653,000 after purchasing an additional 57,290 shares during the last quarter. Kanen Wealth Management LLC acquired a new position in biote in the fourth quarter valued at about $1,791,000. Northern Trust Corp grew its stake in biote by 9.9% during the fourth quarter. Northern Trust Corp now owns 288,336 shares of the company’s stock worth $1,782,000 after buying an additional 25,873 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in shares of biote by 24.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 272,377 shares of the company’s stock worth $1,520,000 after buying an additional 54,302 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Craig Hallum decreased their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.

View Our Latest Analysis on BTMD

biote Company Profile

(Get Free Report)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

See Also

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.